(2005; 12 pages)
WHO Pharmaceuticals Newsletter 2005, No. 01
prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
The aim of this Newsletter is to disseminate information on the safety and efficacy of pharmaceutical products, based on information received from our network of "drug information officers" and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from:
Quality Assurance and Safety:
World Health Organization,
1211 Geneva 27, Switzerland
E-mail address: email@example.com
This newsletter is also available on our Internet website: http://www.who.int/medicines Further information on adverse reactions may be obtained from the WHO Collaborating Centre for International Drug Monitoring, Stora Torget 3, 753 20 Uppsala, Sweden
News & Issues
This is the first issue for the year 2005. The cover page is green, representing, we like to think, the need for fresh ideas and out-of-the-box thinking in pharmacovigilance. Inside you will find the usual format, with items on safety of medicines and their regulation. We welcome additional comments on how we could make this publication more valuable.
Two training programmes/workshops in pharmacovigilance have already been held this year, one in India, as part of the launch of the new system for promoting Indian Pharmacovigilance (details on page 8) and one in Spain, the workshop on 'New Challenges in Clinical Safety, Pharmacovigilance and Vaccine Vigilance' by the International Society of Pharmacovigilance, ISOP. The WHO Collaborating Centre, in Uppsala, will conduct its training course on Pharmacovigilance in May.
Selective Serotonin Reuptake Inhibitors (SSRIs) are again in the news, this time for potential neonatal withdrawal effects in children following SSRI exposure, in utero. Using this as a case-in-evidence (see section on Drugs of Current Interest) we appeal, yet again, to all Member States to step-up reporting to the WHO global database for adverse drug reactions.